OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NAM55

Namwiwat Medical Corp PCL

Medical Equipment, Supplies & DistributionVerified

Namwiwat Medical Corp PCL maintains a strong liquidity position with a current ratio of 8.91, indicating a high ability to meet short-term obligations. However, the company reported negative operating cash flow of -48,123,590 THB and free cash flow of -12,124,070 THB, suggesting cash outflows from operations. The capital expenditure of -33,648,790 THB reflects ongoing investment in long-term assets. Profitability metrics show a return on equity (ROE) of 0.67% and a return on assets (ROA) of 0.58%, both below the typical thresholds for high-performing healthcare firms. The company's operating income of 21,332,120 THB and net income of 13,269,070 THB indicate modest profitability relative to its asset base. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts. Outlook for the current fiscal year shows a projected revenue growth of 0.00%, with no significant changes expected in the next fiscal year. The company's historical revenue of 200,446,110 THB reflects a stable but non-expanding business model. Risk factors include a medium liquidity risk due to negative net cash after subtracting total debt. The dilution risk is assessed as low, with no near-term pressure from share issuance or convertible instruments. The company's debt-to-equity ratio of 0.09 suggests a conservative capital structure. Recent filings and transcripts do not disclose any material events or strategic shifts. The company's financial statements remain consistent with prior periods, with no significant changes in operations or capital structure.

30-day price · NAM-0.18 (-4.8%)
Low$3.52High$3.80Close$3.54As of15 May, 00:00 UTC
Profile
CompanyNamwiwat Medical Corp PCL
TickerNAM.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Namwiwat Medical Corp PCL operates in the medical equipment, supplies, and distribution sector, generating revenue primarily through the sale and distribution of medical devices and related healthcare products.

Classification. The company is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

Namwiwat Medical Corp PCL maintains a strong liquidity position with a current ratio of 8.91, indicating a high ability to meet short-term obligations. However, the company reported negative operating cash flow of -48,123,590 THB and free cash flow of -12,124,070 THB, suggesting cash outflows from operations. The capital expenditure of -33,648,790 THB reflects ongoing investment in long-term assets. Profitability metrics show a return on equity (ROE) of 0.67% and a return on assets (ROA) of 0.58%, both below the typical thresholds for high-performing healthcare firms. The company's operating income of 21,332,120 THB and net income of 13,269,070 THB indicate modest profitability relative to its asset base. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts. Outlook for the current fiscal year shows a projected revenue growth of 0.00%, with no significant changes expected in the next fiscal year. The company's historical revenue of 200,446,110 THB reflects a stable but non-expanding business model. Risk factors include a medium liquidity risk due to negative net cash after subtracting total debt. The dilution risk is assessed as low, with no near-term pressure from share issuance or convertible instruments. The company's debt-to-equity ratio of 0.09 suggests a conservative capital structure. Recent filings and transcripts do not disclose any material events or strategic shifts. The company's financial statements remain consistent with prior periods, with no significant changes in operations or capital structure.
Key takeaways
  • Namwiwat Medical Corp PCL maintains a strong current ratio but faces negative operating and free cash flows.
  • ROE and ROA are below typical thresholds for the healthcare equipment industry.
  • Revenue is concentrated in a single business segment with no geographic diversification.
  • The company's capital structure is conservative, with a low debt-to-equity ratio.
  • No near-term dilution risk is identified, and liquidity remains a medium concern.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$200.4M
Gross profit$91.1M
Operating income$21.3M
Net income$13.3M
R&D
SG&A
D&A
SBC
Operating cash flow-$48.1M
CapEx-$33.6M
Free cash flow-$12.1M
Total assets$2.30B
Total liabilities$323.5M
Total equity$1.98B
Cash & equivalents
Long-term debt$170.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$992.1M$232.8M$174.7M$150.8M
FY-3$1.10B$233.8M$175.7M$98.8M
FY-2$1.10B$264.4M$200.7M$181.3M
FY-1$1.11B$229.0M$180.9M$78.7M
FY0$1.87B$163.5M$101.6M-$65.2M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$1.06B$434.1M
FY-3$1.70B$1.21B
FY-2$2.35B$1.96B
FY-1$2.71B$2.07B
FY0$3.05B$2.00B
PeriodOCFCapExFCFSBC
FY-4$97.8M-$42.3M$150.8M
FY-3-$81.2M-$98.2M$98.8M
FY-2$258.7M-$49.1M$181.3M
FY-1$13.0M-$78.9M$78.7M
FY0$37.9M-$68.7M-$65.2M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$200.4M$21.3M$13.3M-$12.1M
FQ-6$226.5M$44.8M$40.0M$35.1M
FQ-5$316.8M$89.5M$70.9M$68.4M
FQ-4$370.6M$73.4M$56.7M$50.4M
FQ-3$538.1M$83.7M$40.0M$59.9M
FQ-2$389.5M$16.4M$12.5M$11.4M
FQ-1$487.2M$40.2M$22.1M$19.7M
FQ0$455.0M$31.0M$30.8M-$52.9M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$2.30B$1.98B
FQ-6$2.34B$1.95B
FQ-5$2.48B$2.02B
FQ-4$2.71B$2.07B
FQ-3$3.17B$2.11B
FQ-2$2.97B$2.02B
FQ-1$3.07B$2.04B$0.00
FQ0$3.05B$2.00B
PeriodOCFCapExFCFSBC
FQ-7-$48.1M-$33.6M-$12.1M
FQ-6-$151.3M-$47.6M$35.1M
FQ-5$41.1M-$59.8M$68.4M
FQ-4$13.0M-$78.9M$50.4M
FQ-3$52.4M-$15.1M$59.9M
FQ-2-$5.8M-$31.8M$11.4M
FQ-1$109.8M-$45.8M$19.7M
FQ0$37.9M-$68.7M-$52.9M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.98B
Net cash-$170.2M
Current ratio8.9
Debt/Equity0.1
ROA0.6%
ROE0.7%
Cash conversion-3.6%
CapEx/Revenue-16.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricNAMActivity
Op margin10.6%3.9% medp25 -31.3% · p75 14.4%above median
Net margin6.6%2.4% medp25 -30.5% · p75 11.1%above median
Gross margin45.4%46.7% medp25 28.2% · p75 63.1%below median
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-16.8%-4.8% medp25 -11.6% · p75 -2.4%bottom quartile
Debt / equity9.0%17.9% medp25 2.7% · p75 52.2%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 07:51 UTC#1d37f5d0
Market quoteclose THB 3.74 · shares 0.70B diluted
no public URL
2026-05-10 07:51 UTC#9872510a
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 16:54 UTCJob: 62c18a5b